{
  "name": "Galleri Multi-Cancer Early Detection",
  "category": "diagnostic",
  "evidenceGrade": "B",
  "riskProfile": "low",
  "description": "Blood test by GRAIL that screens for 50+ cancer types via cell-free DNA methylation patterns. Detects cancer signal and predicts tissue of origin. Designed as complement to standard screening, especially for cancers without current screening methods.",
  "mechanisms": [
    "Cell-free DNA (cfDNA) methylation analysis",
    "Cancer signal detection across 50+ types",
    "Tissue of origin prediction"
  ],
  "dosage": {
    "standard": "Blood draw, annually",
    "range": "Annually",
    "notes": "Recommended for adults 50+ or high-risk individuals. Complement to (not replacement for) standard screenings. ~0.5% false positive rate."
  },
  "keyFindings": [
    "Detected 50+ cancer types with 51.5% sensitivity in PATHFINDER study",
    "Predicted tissue of origin with 88% accuracy",
    "NHS-Galleri trial (140,000 participants) â€” largest cancer screening trial ever"
  ],
  "interactions": [],
  "sideEffects": [
    "Venipuncture",
    "Psychological impact of results"
  ],
  "contraindications": [
    "Already undergoing cancer treatment (may confound results)"
  ],
  "tags": [
    "diagnostic",
    "cancer-screening",
    "liquid-biopsy",
    "cfdna",
    "preventive"
  ],
  "estimatedMonthlyCost": {
    "low": 75,
    "mid": 80,
    "high": 85,
    "currency": "USD"
  },
  "id": "prod-galleri-multi-cancer-early-detection",
  "sources": [],
  "suppliers": [],
  "communityReports": [],
  "expertOpinions": [],
  "lastUpdated": "2026-02-04T14:50:14.798Z",
  "createdAt": "2026-02-04T14:50:14.798Z"
}